NCT00964743View on ClinicalTrials.gov

Depocyt® With Sorafenib in Neoplastic Meningitis

NATerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Neoplastic Meningitis
Interventions
DRUG

DepoCyt

Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.

DRUG

Sorafenib

Patients received oral sorafenib at 400 mg twice a day

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER